这些手术术式被国家卫健委叫停，此前已在多家大医院开展

Core Viewpoint - The National Health Commission of China has issued bans on two surgical procedures for the treatment of Alzheimer's disease and type 2 diabetes due to safety concerns and lack of sufficient clinical evidence [1][4][9] Group 1: Surgical Procedures Banned - The two banned procedures are "cervical deep lymphatic vessel/lymph node-venous anastomosis" for Alzheimer's treatment and "jejunum-ileum anastomosis" for type 2 diabetes treatment [1][4] - Both procedures have been widely applied in clinical settings despite lacking authoritative guidelines or high-level medical evidence, with only case studies or small sample research available [1][4] - The National Health Commission emphasized that these procedures have been promoted in some hospitals beyond their intended indications, leading to potential safety risks for patients [1][4] Group 2: Clinical Research and Future Directions - The National Health Commission will guide qualified medical institutions to conduct scientific and standardized clinical research on the "cervical deep lymphatic vessel-venous anastomosis" technique for Alzheimer's disease [2] - The "jejunum-ileum anastomosis" has been clinically eliminated for weight-loss metabolic indications due to high rates of severe complications [3][4] - There is a lack of substantial research on the application of "jejunum-ileum anastomosis" for type 2 diabetes, with few studies published in low-impact journals [3][4] Group 3: Emerging Techniques and Challenges - The "cervical deep lymphatic vessel-venous anastomosis" technique is in the early stages of clinical research for neurodegenerative diseases, with some promising individual case results [5][6] - Challenges in the application of this technique include the need for standardized procedures, multidisciplinary management, and more clinical data to support its efficacy [6] - Recent clinical trials registered for Alzheimer's treatment using this technique indicate a growing interest, although there are concerns about its application beyond approved indications [7][8]